Spectrum of Disease in Persons With Human Immunodeficiency Virus Infection in the United States

JAMA: The Journal of the American Medical Association

Volumn 267, Issue 13, 1992, Pages 1798-1805

  Farizo, Karen M ^a   Buehler, James W ^a   Chamberland, Mary E ^a,j   Whyte, Bruce M ^b   Froelicher, Erika Sivarajan ^c   Hopkins, Sharon G ^d   Reed, Christie M ^e   Mokotoff, Eve D ^f   Cohn, David L ^g   Troxler, Sue ^h   Phelps, Ann F ⁱ   Berkelman, Ruth L ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b GEORGIA DEPARTMENT OF HUMAN RESOURCES   (United States)

^c LOS ANGELES COUNTY DEPARTMENT OF HEALTH SERVICES   (United States)

^d Public Health Seattle King County   (United States)

^e TEXAS DEPARTMENT OF STATE HEALTH SERVICES   (United States)

^f MICHIGAN DEPARTMENT OF COMMUNITY HEALTH   (United States)

^g Denver ^*  (United States)

^h LOUISIANA DEPARTMENT OF HEALTH AND HOSPITALS   (United States)

ⁱ Houston Department for Health and Human Services   (United States)

^j NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADOLESCENT; ADULT; AGED; AIDS RELATED COMPLEX; ARTICLE; DEMOGRAPHY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ADMINISTRATION; LUNG TUBERCULOSIS; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MORTALITY; PNEUMONIA; PRIORITY JOURNAL; SEPSIS; SEX DIFFERENCE; UNITED STATES;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADOLESCENT; ADULT; CANDIDIASIS; CD4-POSITIVE T-LYMPHOCYTES; ESOPHAGEAL DISEASES; FEMALE; HIV INFECTIONS; HOSPITALIZATION; HUMAN; LEUKOCYTE COUNT; MALE; MIDDLE AGE; MORBIDITY; OPPORTUNISTIC INFECTIONS; PNEUMONIA, PNEUMOCYSTIS CARINII; POPULATION SURVEILLANCE; RETROSPECTIVE STUDIES; SARCOMA, KAPOSI; UNITED STATES;

EID: 0026519892     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.1992.03480130114035     Document Type: Article

References (47)

1. Centers for Disease Control. Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. MMWR. 1987;36(No. 1S):3S-15S.
2. 1992 Revised Classification System for HIV Infection and Expanded AIDS Surveillance Case Definition for Adolescents and Adults. Atlanta, Ga: Centers for Disease Control; 1991. Draft issued for public comment, November 1991.
3. Centers for Disease Control. HIV/AIDS Surveillance Report. January 1992:1-22.
4. Hollander M, Wolfe DA. Nonparametric Statistical Methods. New York, NY: John Wiley & Sons Inc; 1973:15-25.
5. Clopper CJ, Pearson ES. The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika. 1934;26:404-413.
6. Taylor JMG, Fahey JL, Detels R, Giorgi JV. CD4 percentage, CD4 number, and CD4:CD8 ratio in HIV infection: which to choose and how to use. J Acquir Immune Defic Syndr. 1989;2:114-124.
7. Fahey JL, Taylor JMG, Petels R, et al. The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1. N Engl J Med. 1990;322:166-172.
8. Masur H, Ognibene FP, Yarchoan R, et al. CD4 counts as predictors of opportunistic pneumonias in human immunodeficiency virus (HIV) infection. Ann Intern Med. 1989;111:223-231.
9. Lang W, Perkins H, Anderson RE, Royce R, Jewell N, Winkelstein W. Patterns of T lymphocyte changes with human immunodeficiency virus infection: from seroconversion to the development of AIDS. J Acquir Immune Defic Syndr. 1989;2:6369.
10. Goedert JJ, Biggar RJ, Melbye M, et al. Effect of T4 count and cofactors on the incidence of AIDS in homosexual men infected with human immunodeficiency virus. JAMA. 1987;257:331-334.
11. Nicholson JKA, Spira TJ, Aloisio CH, et al. Serial determinations of HIV-1 titers in HIV-infected homosexual men: association of rising titers with CD4 T cell depletion and progression to AIDS. AIDS Res Hum Retroviruses. 1989;5:205-215.
12. Fernandez-Cruz E, Desco M, Montes MG, Longo N, Gonzalez B, Zabay JM. Immunological and serological markers predictive of progression to AIDS in a cohort of HIV-infected drug users. AIDS. 1990;4:987-994.
13. Stoneburner RL, Des Jarlais DC, Benezra D, et al. A larger spectrum of severe HIV-1-related disease in intravenous drug users in New York City. Science. 1988;242:916-919.
14. Selwyn PA, Feingold AR, Hartel D, et al. Increased risk of bacterial pneumonia in HIV-infected intravenous drug users without AIDS. AIDS. 1988;2:267-272.
15. Selwyn PA, Hartel D, Wasserman W, Drucker E. Impact of the AIDS epidemic on morbidity and mortality among intravenous drug users in a New York City methadone maintenance program. Am J Public Health. 1989;79:1358-1362.
16. Greenberg AE, Thomas PA, Landesman SH, et al. The spectrum of HIV-related disease among outpatients in New York City. In: Proceedings of the Seventh International Conference on AIDS; June 16-21,1991; Florence, Italy. Abstract MS 2456.
17. Fels AOS. Pulmonary effects of AIDS: bacterial and fungal pneumonias. Clin Chest Med. 1988;9:449-457.
18. Cohn DL. Bacterial pneumonia in the HIVinfected patient. Infect Dis Clin North Am. 1991;5:485-507.
19. Schrager LK. Bacterial infections in AIDS patients. AIDS. 1988;2(suppl 1):S183-S189.
20. Witt DJ, Craven DE, McCabe WR. Bacterial infections in adult patients with the acquired immune deficiency syndrome (AIDS) and AIDS-related complex. Am J Med. 1987:82:900-906.
21. Redd SC, Rutherford GW III, Sande MA, et al. The role of human immunodeficiency virus infection in pneumococcal bacteremia in San Francisco residents. J Infect Dis. 1990;162:1012-1017.
22. Centers for Disease Control. Tuberculosis and acquired immunodeficiency syndrome—Florida. MMWR. 1986;35:587-590.
23. Centers for Disease Control. Tuberculosis and AIDS—Connecticut. MMWR. 1987;36:133-135.
24. Centers for Disease Control. Tuberculosis and acquired immunodeficiency syndrome—New York City. MMWR. 1987;36:785-790, 795.
25. Handwerger S, Mildvan D, Senie R, McKinley FW. Tuberculosis and the acquired immunodeficiency syndrome at a New York City hospital: 1978-1985. Chest. 1987;91:176-180.
26. Rieder HL, Cauthen GM, Kelly GD, Bloch AB, Snider DE Jr. Tuberculosis in the United States. JAMA. 1989;262:385-389.
27. Selwyn PA, Hartel D, Lewis VA, et al. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med. 1989;320:545550.
28. Buehler JW, Devine OJ, Berkelman RL, Chevarley FM. Impact of the human immunodeficiency virus epidemic on mortality trends in young men, United States. Am J Public Health. 1990;80:1080-1086.
29. Chu SY, Buehler JW, Berkelman RL. Impact of the human immunodeficiency virus epidemic on mortality in women of reproductive age, United States. JAMA. 1990;264:225-229.
30. Biggar RJ, Horm J, Goedert JJ, Melbye M. Cancer in a group at risk of acquired immunodeficiency syndrome (AIDS) through 1984. Am J Epidemiol. 1987;126:578-586.
31. Harnly ME, Swan SH, Holly EA, Kelter A, Padian N. Temporal trends in the incidence of non-Hodgkin’s lymphoma and selected malignancies in a population with a high incidence of acquired immunodeficiency syndrome (AIDS). Am J Epidemiol. 1988;128:261-267.
32. Kristal AR, Nasca PC, Burnett WS, Mikl J. Changes in the epidemiology of non-Hodgkin’s lymphoma associated with epidemic human immunodeficiency virus (HIV) infection. Am J Epidemiol.’ 1988;128:711-718.
33. Biggar RJ, Burnett W, Mikl J, Nasca P. Cancer among New York men at risk of acquired immunodeficiency syndrome. Int J Cancer. 1989;43: 979-985.
34. Ames ED, Conjalka MS, Goldberg AF, et al. Hodgkin’s disease and AIDS: twenty-three new cases and a review of the literature. Hematol Oncol Clin North Am. 1991;5:343-356.
35. Palefsky J. Human papillomavirus infection among HIV-infected individuals: implications for development of malignant tumors. Hematol Oncol Clin North Am. 1991;5:357-370.
36. Tirelli U, Vaccher E, Zagonel V, et al. Malignant tumors other than lymphoma and Kaposi’s sarcoma in association with HIV infection. Cancer Detect Prev. 1988;12:267-272.
37. Wilkinson M, Carroll PR. Testicular carcinoma in patients positive and at risk for human immunodeficiency virus. J Urol. 1990;144:1157-1159.
38. Schafer A, Friedmann W, Mielke M, Schwartlander B, Koch MA. The increased frequency of cervical dysplasia-neoplasia in women infected with the human immunodeficiency virus is related to the degree of immunosuppression. Am J Obstet Gynecol. 1991;164:593-599.
39. Centers for Disease Control. Risk for cervical disease in HIV-infected women—New York City. MMWR. 1990;39:846-849.
40. Imam N, Carpenter CCJ, Mayer KH, Fisher A, Stein M, Danforth SB. Hierarchical pattern of mucosal candida infections in HIV-seropositive women. Am J Med. 1990;89:142-146.
41. Friese K, Rossol S, Voth R, Hess G, Kreienberg R, Meyerzum Buschenfelde KH. Epidemiological causal infections and immunological results from the HIV Outpatient Department of the Department of Obstetrics and Gynaecology of the University of Mainz. Geburtshilfe Frauenheilkd. 1989;49:385-389.
42. Stein J, Roche N, Usha MW, et al. Gynecologic findings in an HIV positive outpatient population. In: Proceedings of the Seventh International Conference on AIDS; June 16-21,1991; Florence, Italy. Abstract MB 2427.
43. Carpenter CCJ, Mayer KH, Stein MD, Leibman BD, Fisher A, Fiore TC. Human immunodeficiency virus infection in North American women: experience with 200 cases and a review of the literature. Medicine. 1991;70:307-325.
44. Brookmeyer R. Reconstruction and future trends of the AIDS epidemic in the United States. Science. 1991;253:37-42.
45. Brundage JF, McNeil JG, Miller RN, et al. The current distribution of CD4+ T-lymphocyte counts among adults in the United States with human immunodeficiency virus infections: estimates based on the experience of the U.S. Army. J Acquir Immune Defic Syndr. 1990;3:92-94.
46. Graham NMH, Zeger SL, Park LP, et al. Effect of zidovudine and Pneumocystis carinii pneumonia prophylaxis on progression of HIV-1 infection to AIDS. Lancet. 1991;338:265-269.
47. Volberding PA, Lagakos SW, Koch MA, et al. Zidovudine in asymptomatic human immunodeficiency virus infection—a controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. N Engl J Med. 1990;322:941-949.